Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 15;22(22):5403-5407.
doi: 10.1158/1078-0432.CCR-15-1958. Epub 2016 Sep 21.

Molecular Pathways: _targeting Steroid Receptor Coactivators in Cancer

David M Lonard  1 , Bert W O'Malley  2
Affiliations

Molecular Pathways: _targeting Steroid Receptor Coactivators in Cancer

David M Lonard et al. Clin Cancer Res. .

Abstract

Coactivators represent a large class of proteins that partner with nuclear receptors and other transcription factors to regulate gene expression. Given their pleiotropic roles in the control of transcription, coactivators have been implicated in a broad range of human disease states, including cancer. This is best typified by the three members of the steroid receptor coactivator (SRC) family, each of which integrates steroid hormone signaling and growth factor pathways to drive oncogenic gene expression programs in breast, endometrial, ovarian, prostate, and other cancers. Because of this, coactivators represent emerging _targets for cancer therapeutics, and efforts are now being made to develop SRC-_targeting agents, such as the SI-2 inhibitor and the novel SRC stimulator, MCB-613, that are able to block cancer growth in cell culture and animal model systems. Here, we will discuss the mechanisms through which coactivators drive cancer progression and how _targeting coactivators represent a novel conceptual approach to combat tumor growth that is distinct from the use of other _targeted therapeutic agents. We also will describe efforts to develop next-generation SRC inhibitors and stimulators that can be taken into the clinic for the treatment of recurrent, drug-resistant cancers. Clin Cancer Res; 22(22); 5403-7. ©2016 AACR.

PubMed Disclaimer

Conflict of interest statement

DML and BWO are co-founders and hold stock in Coregon, Inc. which is developing steroid receptor coactivator stimulators for clinical use.

Figures

Figure 1
Figure 1
Steroid Receptor Coactivator (SRC) based drugs are predicted to block cancer cell resistance to chemotherapy. SRCs bind to DNA-bound transcription factors (TF) and subsequently recruit co-coactivators such as p300/CBP and CARM1, forming a coactivator complex that drives transcription. In (A), chemotherapeutic agents designed to _target ERα such as selective estrogen receptor modulators (SERMS) and degraders (SERDs), HER2 (herceptin and lapitanib), or PI3K (buparlisib) can not block coactivator stimulation of other growth promoting pathways driven through E2F1 or NF-κB in SRC-3-overexpressing cancer cells. (B) In contrast, a SRC _targeting SMI is predicted to simultaneously inhibit constitutively active ERα mutants that arise in endocrine-therapy resistant breast cancers and different growth pathways that are concomitantly activated when SRCs are overexpressed, blocking their ability to access alternative growth pathways that become active in endocrine therapy- or chemotherapy-resistant cancer cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835–9. - PMC - PubMed
    1. Lonard DM, O’Malley BW. Nuclear receptor coregulators: modulators of pathology and therapeutic _targets. Nat Rev Endocrinol. 2012;8:598–604. - PMC - PubMed
    1. Onate SA, Tsai SY, Tsai MJ, O’Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270:1354–7. - PubMed
    1. Dasgupta S, Lonard DM, O’Malley BW. Nuclear receptor coactivators: master regulators of human health and disease. Annu Rev Med. 2014;65:279–92. - PMC - PubMed
    1. Xu J, Wu RC, O’Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. 2009;9:615–30. - PMC - PubMed

MeSH terms

Substances

  NODES
Association 1
twitter 2